Abstract
Antiplatelet drugs are the cornerstone of therapy in many cardiovascular conditions. With the current success and increased use of transcatheter aortic valve implantation (TAVI), the use of antiplatelet therapy is considered part of the medical therapy for these patients. Clinicians caring for these patients need to have a thorough understanding of the pharmacology, pharmacokinetics, pharmacodynamic, and clinical efficacy and safety of commonly used antiplatelet therapy. While aspirin therapy is widely used, dual antiplatelet therapy with clopidogrel has become part of standard of care. Despite the extensive experience with clopidogrel, there are limitations such as drug interactions, metabolism genetic polymorphisms, and variability in the antiplatelet response. More predictable and more potent antiplatelet agents, prasugrel and ticagrelor, have demonstrated superior reductions in ischemic endpoints as part of dual antiplatelet therapy compared to clopidogrel, but at the cost of more major bleeding in patients with an acute coronary syndrome. Significant research needs to be conducted in the setting of TAVI to help define the optimal antiplatelet regimen.
Keywords: Aspirin, clopidogrel, prasugrel, ticagrelor, antiplatelet agents, P2Y12 inhibitors.
Current Pharmaceutical Design
Title:Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor
Volume: 22 Issue: 13
Author(s): Paul P. Dobesh, Sara Varnado and Meagan Doyle
Affiliation:
Keywords: Aspirin, clopidogrel, prasugrel, ticagrelor, antiplatelet agents, P2Y12 inhibitors.
Abstract: Antiplatelet drugs are the cornerstone of therapy in many cardiovascular conditions. With the current success and increased use of transcatheter aortic valve implantation (TAVI), the use of antiplatelet therapy is considered part of the medical therapy for these patients. Clinicians caring for these patients need to have a thorough understanding of the pharmacology, pharmacokinetics, pharmacodynamic, and clinical efficacy and safety of commonly used antiplatelet therapy. While aspirin therapy is widely used, dual antiplatelet therapy with clopidogrel has become part of standard of care. Despite the extensive experience with clopidogrel, there are limitations such as drug interactions, metabolism genetic polymorphisms, and variability in the antiplatelet response. More predictable and more potent antiplatelet agents, prasugrel and ticagrelor, have demonstrated superior reductions in ischemic endpoints as part of dual antiplatelet therapy compared to clopidogrel, but at the cost of more major bleeding in patients with an acute coronary syndrome. Significant research needs to be conducted in the setting of TAVI to help define the optimal antiplatelet regimen.
Export Options
About this article
Cite this article as:
Dobesh P. Paul, Varnado Sara and Doyle Meagan, Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor, Current Pharmaceutical Design 2016; 22 (13) . https://dx.doi.org/10.2174/1381612822666151208120106
DOI https://dx.doi.org/10.2174/1381612822666151208120106 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Current Cardiology Reviews Platelets as Potential Immunomodulators: Is There a Role for Platelet Toll-Like Receptors?
Current Immunology Reviews (Discontinued) Adenotonsillar Disease
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives
Current Drug Targets Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus
Current Pharmaceutical Biotechnology Editorial [Hot topic:Thromboembolism in Patients with Malignancy (Guest Editor: Ioannis Starakis)]
Cardiovascular & Hematological Disorders-Drug Targets The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews Quorum Sensing Inhibitors from the Sea: Lessons from Marine Symbiotic Relationships
Current Organic Chemistry Microbial Biofilms: Impact on the Pathogenesis of Periodontitis, Cystic Fibrosis, Chronic Wounds and Medical Device-Related Infections
Current Topics in Medicinal Chemistry Odontogenic Infections in the Etiology of Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Prevalence of Dilated Cardiomyopathy in HIV-Infected African Patients Not Receiving HAART: A Multicenter, Observational, Prospective, Cohort Study in Rwanda
Current HIV Research Long-term Outcomes of Mitral Valve Repair Versus Replacement for Degenerative Disease: A Systematic Review
Current Cardiology Reviews Aspergillus – Classification and Antifungal Susceptibilities
Current Pharmaceutical Design Human Heart Failure: A Proteomics Perspective
Current Proteomics Management of Asymptomatic Severe Aortic Stenosis
Current Cardiology Reviews Pneumonia Caused by Staphylococcus aureus
Current Respiratory Medicine Reviews Aspirin Resistance in Cardiovascular Disease: Pathogenesis, Diagnosis and Clinical Impact
Current Pharmaceutical Design From Vancomycin to Oritavancin: The Discovery and Development of a Novel Lipoglycopeptide Antibiotic
Anti-Infective Agents in Medicinal Chemistry Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews